Filing Flows › BioStem Technologies (BSEM) › Q2 2026
BioStem Technologies (BSEM) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 12, 2026
BioStem Technologies (BSEM) reported revenue of $7.9M for the second quarter 2026 (Q2 2026), -28% from a year earlier. Operating margin was -106.3%, net loss $9.0M (113.6% of revenue).
BioStem Technologies, Q2 2026: revenue $7.9M (-28% year over year), operating margin -106.3%, net loss $9.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.9M | — | -28% |
| Operating profit | −$8.4M | — | — |
| Net earnings | −$9.0M | — | — |
What changed
Revenue was $7.9M in Q2 2026, down 28% year over year. Hospital was the largest line at 85% of revenue. Physician Office lost $9.9M year over year (down 90%), 322% of the total change.
Gross margin was 61.3%, down 32.5 points from a year earlier. Operating costs exceeded revenue by $8.4M, an operating margin of -106.3%. Operating expenses grew 30% against a revenue fall of 28%. The fastest-growing cost line was Other operating costs (+1035%). The quarter ended with a net loss of $9.0M.
Questions
What was BioStem Technologies' revenue in the second quarter 2026?
BioStem Technologies (BSEM) reported revenue of $7.9M for the second quarter 2026 (Q2 2026), -28% from a year earlier.
Was BioStem Technologies profitable in the second quarter 2026?
Operating loss was $8.4M (-106.3% of revenue) and net loss $9.0M.